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Pharmacogenetics of Selective Serotonin Reuptake
Inhibitors and Associated Adverse Drug Reactions
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The selective serotonin reuptake inhibitors (SSRIs) have become one of the
most widely prescribed classes of drugs. They are relatively safe for the
pharmacologic treatment of various psychiatric disorders; however, certain
patients cannot tolerate some adverse drug reactions associated with this drug
class. In addition, clinicians currently have no way to predict who will
respond appropriately to a given SSRI, and the paradigm of trial and error is
especially distressing for patients with mental illness. Pharmacogenetic
association studies may provide insight into which genetic polymorphisms
might be clinically relevant for individualizing pharmacotherapeutic
regimens. Thus, we reviewed and summarized the literature regarding the
pharmacogenomics of SSRI-associated adverse drug reactions. This growing
body of knowledge may inform subsequent design of pharmacogenetic studies
with respect to adverse drug reactions. As we appreciate the many pharmaco-
logic mechanisms related to adverse drug reactions and gain polymorphic
functional data, we will have opportunities to refine hypotheses for future
pharmacogenetic association analyses.
Key Words: selective serotonin reuptake inhibitor, SSRI, pharmacogenetics,
adverse drug reactions, antidepressants.
(Pharmacotherapy 2009;29(7):822–831)
OUTLINE
Serotonergic Genes
Serotonin Transporter Gene (SLC6A4)
Serotonin Transporter Promoter Region (SERTPR)
Variant
Serotonin Transporter, Second Intron Variable
Number of Tandem Repeats (STin2)
Serotonin 2A Receptor Gene (HTR2A)
HTR2A Variants T102C (rs6313) and -1438G/A
Serotonin 3A Receptor Gene (HTR3A)
Serotonin 3B Receptor Gene (HTR3B)
Tryptophan Hydroxylase Gene (TPH)
Dopaminergic Genes
Glutamatergic Genes
Monoaminergic Genes
Monoamine Oxidase A Gene (MAOA)
Cyclic Adenosine 3′,5′-Monophosphate Response
Element Binding Protein 1 Gene (CREB1)
Metabolic Genes
Cytochrome P450 2D6 Gene (CYP2D6)
Cytochrome P450 2C19 Gene (CYP2C19)
Emerging Trends
Conclusion
Selective serotonin reuptake inhibitors (SSRIs)
have become one of the most widely prescribed
classes of drugs. Antidepressants took over the top
ranking for prescriptions dispensed in the United
States in 2007, with 232.7 million.1 Overall, the
SSRIs have fewer adverse drug reactions than the
other classes of antidepressants, such as tricyclic
or heterocyclic antidepressants and monoamine
oxidase inhibitors. However, some patients
discontinue therapy because of intolerable adverse
drug reactions. Clinicians currently have no way
to predict who will respond appropriately to a
given SSRI, and the paradigm of trial and error is
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especially distressing for patients with mental
illness. Once SSRI therapy is started, 4–8 weeks
may be required to establish efficacy. During this
period, adverse events may cause some patients
to stop treatment before their symptoms of
depression improve. However, such reactions
might be avoided if clinicians could predict them
on the basis of a patient’s genetic profile and,
thus, individualize drug therapy.
Most of the pharmacogenetics literature related
to SSRI use has focused on efficacy as the primary
outcome. A thorough review of this literature
recognized the fundamental challenge of selecting
appropriate candidate polymorphisms for making
efficacy associations when the exact mechanism
by which SSRIs reduce depression symptoms is
not entirely certain.2
Candidate polymorphisms for adverse drug
reactions have traditionally been selected on the
basis of their potential involvement in the pharmaco-
kinetic or pharmacodynamic properties of SSRIs.
Because it is easiest to objectively measure plasma
concentrations and pharmacokinetic parameters,
much initial attention focused on metabolic enzymes,
particularly those in the cytochrome P450 (CYP)
family. In the past few years, researchers began to
question the clinical relevance of this information
for SSRIs due to a wide therapeutic index and the
lack of evidence reliably supporting a link between
tolerability and plasma concentrations.3 Most
recently, though, association studies of adverse
drug reactions have focused on the pharmaco-
dynamic effects of these drugs that may be medi-
ated by alterations in transporters and postsynaptic
receptors due to genetic variation.
This review summarizes the current pharmaco-
genetic studies that were designed to test associa-
tions between SSRI-related adverse drug reactions
and genetic variation, as this body of literature is
expanding quickly in the 21st century. However,
it has many limitations, as most of these studies
are retrospective or have open-label designs, or
are case reports. Regardless, the combined results
of these studies illustrate trends observed from
pharmacogenetic association analyses as they
relate to global and specific adverse drug reactions.
To compare results across the genetic polymorphisms
tested, we categorized each study according to
the drug-induced adverse drug reactions and the
specific SSRIs investigated.
Serotonergic Genes
Serotonin Transporter Gene (SLC6A4)
The serotonin transporter (SERT) is the primary
target for SSRIs; therefore, the gene that encodes
SERT, SLC6A4, is an obvious candidate for evalu-
ations of efficacy and adverse drug reactions.
Most SSRI pharmacogenetic studies of adverse
drug reactions have focused on SLC6A4. In
particular, the gene-linked polymorphic promoter
region with a 44–base pair insertion-deletion,
called SERTPR, has a long (L) variation of a 16-
repeat sequence and a short (S) variation of 14
repeats that has been associated with lower levels
of genetic transcription.4 The L allele has been
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Figure 1. Theoretical mechanism for increased selective
serotonin reuptake inhibitor (SSRI)–induced adverse drug
reactions (ADRs) with the SS genotype at the serotonin
transporter (SERT) promoter region (SERTPR). The net
effect is an overabundance of postsynaptic serotonin (5-HT):
SERTPR SS genotype decreases SERT density, which
decreases 5-HT reuptake, thereby allowing SSRI blockade to
greatly increase 5-HT in the synapse that results in
intolerable ADRs. The left side of the figure illustrates the
mechanism for the LL genotype: SERTPR LL genotype
increases SERT density, which increases 5-HT reuptake,
thereby allowing SSRI blockade to mildly increase 5-HT in
the synapse that results in well-tolerated SSRI therapy.
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shown to result in an increased maximum velocity
of the enzyme-catalyzed reaction for serotonin
reuptake compared with the S allele.5 Therefore,
lower levels of SERT-related transcription in
patients with the S allele could increase the
proportion of reuptake transporters that are
saturated; this effect may drastically increase
synaptic serotonin levels and potentially result in
adverse drug reactions (Figure 1).
In addition to SERTPR, the second intron of
SLC6A4 contains a variable number of tandem
repeats (VNTR) polymorphisms called STin2.6
The variation in STin2 consists of 9, 10 and 12
repeats known as STin2.9, STin2.10, and
STin2.12, respectively. Affinity for serotonin
reuptake is lower among individuals homozygous
for STin2.12 than among heterozygotes.6
Therefore, STin2.12 could also increase serotonergic
signaling and adverse drug reactions. Table 1
shows results of association studies focused on
the relationship between polymorphisms of the
serotonin transporter and SSRI-associated adverse
drug reactions.7–16
Serotonin Transporter Promoter Region
(SERTPR)
The population of one Japanese study consisted
of 54 subjects; however, as only four of them had
the LL genotype for SERTPR, investigators were
not able to find any statistically significant
associations.7 One year later (2003), other
researchers determined that the rates of insomnia
and agitation were higher with the SS genotype
than with others.8 They also performed logistic
regression using baseline depression severity and
anxiety-somatization factors as covariates. In
this regression model, SS genotype was still a
significant predictor associated with each
outcome (insomnia p=0.02, agitation p=0.01).
In 2004, a somewhat contradictory finding
suggested an association between increased SSRI-
induced nighttime motor activity and the LL
genotype.9 Although actographically measured
motor activity indicated a statistically significant
difference, clinical assessments of retardation and
agitation showed no difference between genotypes.
Also in 2004, a large study demonstrated an
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Table 1. Summary of Studies Related to SLC6A4 Variants SERTPR and STin2
Polymorphism, Study
Design, Duration,
and Population SSRI Results
SERTPR, STin2
Prospective, 6 wks, Fluvoxamine No associations with nausea were noted
Japanese (n=54)7
Prospective, ≥ 6 wks, Fluoxetine, paroxetine, sertraline, No associations with total ADRs were noted
Dutch (n=209)15 citalopram, fluvoxamine
SERTPR
Prospective, 12 wks, Fluoxetine SS genotype associated with increased insomnia
American (n=36)8 (78% vs 22%, p=0.005) and agitation (67% vs 7%,
p=0.001) vs LL and SL genotypes
Prospective, 5 days, Paroxetine, citalopram LL genotype associated with increased nighttime
German (n=22)9 motor activity (p<0.001)
Prospective, 8 wks, Paroxetine Number of S alleles had linear relationship with
American (n=121)10 discontinuation (SS 50%, LL 12%, SL 23%; p<0.05
for all time points); SS genotype also associated
with increased ADR severity vs LL (p=0.02)
Prospective, 6 wks, Sertraline No associations with ADRs were noted
Australian and
Malaysian (n=35)11
Prospective, 6 wks, Paroxetine, fluvoxamine No associations with discontinuation, nausea, or
Japanese (n=100)12 total ADRs were noted
Retrospective, case- Fluoxetine, paroxetine, sertraline, No associations with extrapyramidal symptoms
control, Swedish citalopram, fluvoxamine were noted
(n=19)13
Prospective, 12 wks, Paroxetine No associations with nausea were noted
Japanese (n=72)14
Prospective, 12 wks, Citalopram LALA genotype associated with lower ADR burden
American (n=1655)16 (7% vs 13%, p=0.03) vs other genotypes without
LA allele
SSRI = selective serotonin reuptake inhibitor; ADR = adverse drug reaction.
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association between the number of S alleles and
the probability of discontinuation due to adverse
drug reactions.10 The SS genotype was also
associated with greater severity of adverse drug
reactions.
Despite these early positive findings, a 2006
study in Australia and Malaysia involving 35
Caucasian and Asian subjects yielded no associ-
ation between adverse drug reactions and the SS
genotype.11 An evaluation of depressed Japanese
patients randomly chosen to receive paroxetine
or fluoxetine showed no associations of the SS
genotype with discontinuation, nausea, or total
adverse drug reactions.12 Swedish investigators
retrospectively screened a national database to
determine associations of SERTPR with SSRI-
induced extrapyramidal symptoms and found
none.13
In 2007, investigators reported the lack of
associations between SERTPR polymorphisms
and paroxetine-induced nausea.14 Researchers in
the Netherlands conducted the largest study
regarding SSRI-induced adverse drug reactions.15
Like the others, they found no statistically signi-
ficant associations, but the SS and SL genotype
tended to increased the risk of adverse drug reac-
tions compared with the LL reference genotype.
The Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) trial elucidated an
association between a decreased burden of
adverse drug reactions and the LA allele.16 In the
total sample, the LALA genotype reduced the
absolute risk of adverse drug reactions by 6%. To
our knowledge, this work is the largest adverse
drug reaction association study of citalopram that
was also designed to examine the effect of the
additional A>G substitution that SERTPR contains.
Serotonin Transporter, Second Intron Variable
Number of Tandem Repeats (STin2)
In addition to the SLC6A4 SERTPR variant,
STin2 may be associated with alternations in
serotonergic neurotransmission. However, most
studies of this variant have yielded no significant
associations. For example, the aforementioned
Dutch study also examined STin2 and found no
statistically significant associations.15 A Japanese
study found no associations among 54 patients
because of a lack of subjects in the 10/10
genotype group.7 Given the findings from these
two small studies, the role of STin2 in the
development of SSRI-associated adverse drug
reactions is still relatively unknown.
Serotonin 2A Receptor Gene (HTR2A)
The serotonin 2A receptor encoded by HTR2A
is the next logical target for pharmacogenetic
studies because the mechanism of action of SSRIs
is to increase synaptic serotonin, which acts on
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Table 2. Summary of Studies Related to HTR2A Variants T102C and -1438 G/A
Polymorphism, Study
Design, Duration,
and Population SSRI Results
T102C
Retrospective, case- Fluoxetine, paroxetine, sertraline, No associations with extrapyramidal symptoms were
control, Swedish citalopram, fluvoxamine noted
(n=19)13
Prospective, 12 wks, Paroxetine No associations with nausea were noted
Japanese (n=72)14
Prospective, 8 wks, Paroxetine CC genotype associated with more discontinuation
American (n=120)18 than CT and TT (45% vs 15%, p=0.001) and increased
ADR severity (p=0.03)
-1438 G/A
Prospective, 6 wks, Paroxetine, fluvoxamine In paroxetine-treated patients, GG genotype associated
Japanese (n=100)12 with more severe nausea (30% vs 5%, p=0.014) and all
ADRs (70% vs 40%, p=0.043) vs GA and AA genotypes
Prospective, 6 wks, Fluvoxamine No associations with nausea were noted
Japanese (n=54)20
Prospective, 12 wks, Fluvoxamine Single G allele increased risk of gastrointestinal adverse
Japanese (n=96)21 effects by 2.171-fold (p=0.041); two G alleles increased
risk by 2.926-fold (p=0.008)
Prospective, ≥ 6 wks, Fluoxetine, paroxetine, sertraline, GG genotype more likely than GA and AA genotypes to
American (n=81)22 citalopram, escitalopram have sexual dysfunction (odds ratio 3.6, p=0.046)
SSRI = selective serotonin reuptake inhibitor; ADR = adverse drug reaction.
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postsynaptic receptors, such as the 2A subtype.
Serotonin 2A receptors play an important role in
agitation, insomnia, and sexual dysfunction.17
Several single-nucleotide polymorphisms (SNPs)
have been characterized for HTR2A. The most
frequently studied ones are T102C and -1438 G/A,
where the CC genotype of T102C is in perfect
linkage disequilibrium with the GG genotype of
-1438 G/A.18 The C allele of T102C reduces
expression of serotonin 2A receptors, which
could hasten their saturation and increase
serotonergic activity, resulting in adverse drug
reactions.19
Table 2 summarizes work done to elucidate the
relationship between HTR2A receptor variation
and SSRI-associated adverse drug reactions.12–14,
18, 20–22
HTR2A Variants T102C (rs6313) and -1438G/A
Researchers also evaluated associations
between paroxetine-induced adverse drug reac-
tions and the HTR2A T102C SNP.18 Paroxetine-
treated patients with the CC genotype were more
likely to discontinue treatment than the CT and
TT genotypes, and their adverse drug reactions
were also worse.
A 2007 evaluation of the frequency of nausea
in Japanese patients treated with paroxetine
showed no associations with the T102C variant.14
This was also true for other research conducted
in Japan that yielded no significant relationship
between the -1438 G/A genotype and fluvox-
amine-induced nausea.20 In follow-up, other
investigators found that a single -1438G allele
increased the risk of fluvoxamine-induced
gastrointestinal adverse effects, whereas two
copies of the G allele increased the risk even
more.21 Of interest, another group found no
association with fluvoxamine, but they did find
an association between the GG genotype and the
severity of paroxetine-induced nausea and overall
adverse drug reactions.12
Among patients who had been evaluated for
SSRI-induced extrapyramidal symptoms, no
associations with -1438 G/A were found.13 They
were additionally screened for many other
HTR2A polymorphisms, including Thr25Asn,
C516T, and His452Tyr; none were associated the
symptoms. However, given the small sample
size, these results may not be surprising.
Investigators examined the relationship
between the -1438 G/A variant and SSRI-asso-
ciated sexual dysfunction using the Changes in
Sexual Functioning Questionnaire,22 a validated
instrument. They found an association between
the GG genotype and SSRI-induced sexual
dysfunction. This investigation is probably the
largest pharmacogenetic study to focus on this
adverse effect.
Serotonin 3A Receptor Gene (HTR3A)
The serotonin 3A receptor is another logical
target for pharmacogenetic studies because the
action of SSRI on synaptic serotonin also affects
the 3A subtype of postsynaptic receptors.
Serotonin 3 receptors play an important role in
mediating gastrointestinal adverse drug reactions,
including diarrhea, nausea, and emesis.23
Several variants have been characterized for
HTR3A; those most frequently studied are C195T
and Pro16Ser (C178T). The former, the C195T
SNP, has not been shown to involve any
functional change, but the nonsynonymous
Pro16Ser mutation heightened expression of
serotonin 3A receptors.24 This increase in
postsynaptic receptors could balance the rise in
serotonin due to reuptake blockade and,
ultimately, protect against adverse drug reactions.
Table 3 summarizes the literature regarding
serotonin 3 receptor variants and SSRI
responses.12, 14, 23 From those studies, it appears
that genetic variability in the HTR3A receptor
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Table 3. Summary of Studies Related to HTR3A and HTR3B Variants
Polymorphism, Variants,
Study Design, Duration, Population SSRI Results
HTR3A C178T, HTR3B -100_102/AAG ins-del Paroxetine, No associations with ADRs were noted
Prospective, 6 wks, Japanese (n=100)12 fluvoxamine
HTR3A A14371G, HTR3B -100_102/AAG ins-del Paroxetine AAG deletion variant associated with more nausea
Prospective, 6 wks, Japanese (n=72)14 vs homozygous for AAG insertion allele
(62% vs 38%, p=0.0028)
HTR3A Pro16Ser and C195T, HTR3B Tyr129Ser Paroxetine HTR3B Tyr/Tyr genotype increased risk of nausea
Prospective, ≥ 2 wks, Japanese (n=78)23 (odds ratio 3.95, p=0.048)
SSRI = selective serotonin reuptake inhibitor; ins-del = insertion-deletion; ADR = adverse drug reaction.
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may not be related to SSRI-associated adverse
drug reactions.
Serotonin 3B Receptor Gene (HTR3B)
The postsynaptic serotonin 3B receptor
subtype is another candidate for pharmacogenetic
studies given its position in the synapse. Several
variants of HTR3B have been characterized, the
most frequently studied of which are Tyr129Ser
and the -100_-102AAG insertion-deletion. In
terms of function, the AAG insertion-deletion
may alter the structure and translational effi-
ciency of messenger RNA, whereas consequences
of the Tyr129Ser nonsynonymous mutation are
not well characterized.25
In the field of oncology, the AAG deletion has
been associated with an increased frequency of
chemotherapy-induced emesis. This adverse
event may be due to a decrease in receptor
translation that results in fewer postsynaptic
receptors, thereby making them more saturated,
with increased serotonergic activity and a higher
frequency of adverse drug reactions.26
In psychiatry, several research groups have
examined the relationship between gastrointestinal
adverse effects and HTR3B receptor genetic
variability, as summarized in Table 3.12, 14, 23
Applying a logistic regression model, the first
group reported an association between the
Tyr/Tyr genotype of Tyr129Ser and a heightened
risk of paroxetine-induced nausea.23 In 2007,
investigators showed an association between the
-100_-102AAG deletion variant and a higher
frequency of paroxetine-induced nausea but no
association with Tyr129Ser.14 They also screened
for and tested many other polymorphisms and
found no significant associations. Given these
findings, the role of the HTR3B receptor and
SSRI-associated nausea is still unknown.
Tryptophan Hydroxylase Gene (TPH)
Tryptophan hydroxylase, or TPH, is the rate-
limiting enzyme that catalyzes synthesis of
serotonin from tryptophan. Increased function of
this enzyme could raise serotonin levels and,
therefore, potentiate serotonergic effects and
adverse drug reactions due to SSRIs. The A allele
of the tryptophan hydroxylase A218C polymor-
phism has been associated with a slowed
therapeutic response to fluvoxamine.27 However,
whether was this is due to a functional change in
the enzyme is unclear.
In 2002, scientists investigated the relationship
between the tryptophan hydroxylase A218C
variant and fluvoxamine-induced nausea in a 6-
week prospective study.7 They found no
significant associations in their population of 54
Japanese patients.
Dopaminergic Genes
In addition to serotonergic genes, dopaminergic
genes have been examined in relation to SSRI-
associated adverse drug reactions. Data from
imaging studies of the human striatum have
associated the A1 allele of the dopamine2
receptor gene (DRD2) Taq1A polymorphism with
reduced binding of the D2 receptor.28 This lower
striatal density of D2 receptors among A1 allele
carriers may mean that the receptors could be
more rapidly saturated by dopamine. Because
several SSRIs have binding affinity for the
dopamine reuptake transporter (DAT), patients
with the DRD2 Taq1A A1 allele could be at
particular risk for having dopaminergic-
associated adverse drug reactions if they use
SSRIs.
Several dopaminergic genes were investigated
in the 2006 retrospective study of 20 Swedish
patients.13 The DRD2 Taq1A A1 allele was
associated with SSRI-induced extrapyramidal
symptoms. The group of patients who had these
symptoms included significantly more carriers of
the A1 allele than a control group pooled from
the European literature (32% vs 15%, p=0.017).
In addition to the DRD2 Taq1A variant, both
the DAT VNTR and the dopamine 3 receptor
(DRD3) Msc1 restriction fragment length poly-
morphisms have not been not associated with
SSRI-induced adverse drug reactions, specifically
extrapyramidal symptoms. Therefore, variation
in the dopaminergic system is unlikely to be a
major contributor to these reactions.
Glutamatergic Genes
Scientists have recognized potential effects of
the glutamate system on treatment-emergent
adverse drug reactions. Because glutamate is one
of the most abundant excitatory neurotransmitters
in the central nervous system, genetic variation
in glutamate receptors may influence neurotrans-
mission in a way not yet fully appreciated.
Despite this lack of a clear mechanism, recent
genomewide association analyses in the STAR*D
cohort revealed a potential link between ionotropic
glutamate receptors and suicidal ideation. The
largest pharmacogenomics association analysis
related to SSRI treatment-emergent suicidal
ideation was reported in 2007.29 The study
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population of 1862 was derived from STAR*D
subjects whose genotypes were evaluated for 68
candidate genes with 768 SNPs. The CC
genotype at SNP rs2518224 of GRIK2, which
encodes glutamate kainate receptor subunit
GluR6, was associated with treatment-emergent
suicidal ideation, as measured by using the Quick
Inventory of Depressive Symptomatology–
Subject Rated (QIDS-SR) tool (odds ratio 8.23,
permutation p<0.003). In addition, the G allele
at SNP rs4825476 of GRIA3, which encodes
glutamate AMPA receptor subunit AMPA3, was
also associated with suicidal ideation (odds ratio
1.94, permutation p<0.01).
These data are intriguing and will help us learn
more about the role of glutamatergic neurotrans-
mission in depression and the occurrence of
treatment-emergent suicidal ideation.
Monoaminergic Genes
Monoamine Oxidase A Gene (MAOA)
Monoamine oxidase A is an enzyme that
catalyzes oxidation of all monoamine neurotrans-
mitters. Monoamine oxidase inhibitors were
among the first antidepressants available for the
treatment of major depression. Therefore,
decreased function of this enzyme may be
associated with increased monoaminergic effects
from SSRIs.
Overall, MAOA polymorphisms have been
examined in a variety of association studies
involving anger and anxiety. However, the first
study performed to directly assess functional
effects elucidated no significant differences
among them.30 In 2003, an investigation of the
MAOA-VNTR polymorphism found that patients
with low plasma levels of fluvoxamine appeared
to be more pharmacodynamically sensitive to
nausea.20 Therefore, investigators extracted a
post hoc subgroup of 35 patients who had below-
average plasma levels, and the MAOA-VNTR
allele 1 was more common in patients without
nausea (p=0.02). However, this study has not
been replicated; thus, the role of MAOA-VNTR in
SSRI-associated adverse drug reactions is still
unknown.
Cyclic Adenosine 3′,5′-Monophosphate Response
Element Binding Protein 1 Gene (CREB1)
The cyclic adenosine 3′,5′-monophosphate
(cAMP) response element binding protein,
CREB1, binds cAMP response elements and
induces transcription after stimulation of the
cAMP pathway downstream of the monoamine
receptors.
In 2007, an association analysis involved 1447
STAR*D subjects whose genotypes were examined
at five SNPs from regions in and surrounding the
candidate gene CREB1.31 In a subgroup of 539
men, SNP rs4675690 (which is 3′ to the coding
region) was associated with treatment-emergent
suicidal ideation in the first 30 days (odds ratio
2.3, permutation p<0.003), as measured by using
the Quick Inventory of Depressive Symptomato-
logy–Clinician Rated (QIDS-C).
In subsequent studies, this CREB1 SNP was
also associated with brain activation of neural
networks implicated in processing aversion
responsiveness to angry faces.32 These results,
taken with those presented earlier,29 offer us new
directional hypotheses concerning SSRI-associated
adverse drug reactions.
Metabolic Genes
Cytochrome P450 2D6 Gene (CYP2D6)
A substantial part of the literature has focused
on pharmacokinetic changes that may occur as a
result of genetic variability in the CYP isoenzyme
system, specifically CYP2D6. Because this
isoenzyme is well characterized in terms of its
specific substrates and inhibitors or inducers, it
would make sense that changes in drug metabo-
lism may alter outcomes. However, identifying
exactly how each CYP2D6 variant should be
classified in terms of metabolic status has proven
difficult. The theory regarding SSRI-related
adverse drug reactions and CYP2D6 metabolism
was based on the premise that genetic variants
conferring poor-metabolizer status should raise
serum concentrations of SSRIs, possibly
potentiating the serotonergic effects and increase
adverse drug reactions. The Evaluation of
Genomic Applications in Practice and Prevention
(EGAPP) Working Group recently cast doubt on
this theory, citing a lack of evidence to support or
refute the theoretical benefit of CYP2D6
genotyping in the treatment of depression with
SSRIs.3
In 2003, 120 elderly patients were grouped as
poor (homozygous null), intermediate (null
allele and *41, *10, or *9), ultrarapid (*1 or *2
duplicates), or extensive (all other) metabolizers.18
For analysis, the poor- and intermediate-
metabolic groups were combined and compared
with extensive and ultrarapid metabolizers.
Overall, no significant differences in adverse drug
reaction rates were found between these groups.
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A study in 2004 addressed fluoxetine-induced
adverse drug reactions among patients in New
Zealand.33 It uncovered no significant difference
between extensive (*1 with *1, *2, *9, or *10)
and poor (*4/*4, *4/*5) metabolizers. Follow-up
investigation in Japanese patients demonstrated
no association between metabolic status and
fluvoxamine-induced nausea or plasma levels of
fluvoxamine.34 Subjects were stratified as
extensive (*1/*1), intermediate (*1/*5, *1/*10),
or poor (*5/*10, *10/*10) metabolizers. Further
research in Japanese patients in 2006 revealed no
significant difference between paroxetine-
induced nausea and extensive (*1/*1, *1/*10) or
poor (*1/*5, *5/*10, *10/*10) metabolism.23
Among Swedish patients with SSRI-induced
extrapyramidal symptoms, nonfunctional allelic
frequency (*4) did not statistically differ from
that observed in the European population.13
Overall, the authors inferred that metabolic
status did not affect the risk of extrapyramidal
symptoms. A Cox-regression study in Japan
showed a significantly higher risk of fluvoxamine-
induced gastrointestinal adverse effects among
low metabolizers (*1/*5, *5/*10, *10/*10)
compared with normal metabolizers (*1/*1,
*1/*10).21
Table 4 summarizes pharmacogenetic investi-
gations performed to examine the role of CYP2D6
on SSRI-associated adverse drug reactions.13, 14, 18,
21, 23, 33, 34 Data from most studies specifically
addressing the relationship between differences
in CYP2D6 metabolic activity and SSRI-associ-
ated adverse drug reactions have been negative.
Therefore, although this isoenzyme is extremely
important in drug metabolism, its role in the
development of these adverse drug reactions is
still debatable. This fact may limit the utility of
incorporating specific testing for CYP2D6 into
clinical practice.
Cytochrome P450 2C19 Gene (CYP2C19)
Given its role in the metabolism of antidepres-
sants, CYP2C19 has also been examined in
relation to SSRI-associated adverse drug reactions.
Examining 53 Chinese patients in 2006,
scientists found no significant difference in
citalopram-induced adverse effects among poor
(*2/*2, *2/*3, *3/*3), extensive homozygous
(*1/*1), and extensive heterozygous (*1/*2 or
*3) metabolizers.35 However, oral clearance of
citalopram was lower in poor metabolizers than
in extensive homozygous (p=0.001) or
heterozygous (p=0.020) metabolizers. Despite
these potential pharmacogenetic differences, the
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Table 4. Summary of Studies Related to Cytochrome P450 2D6 Metabolic Status
Polymorphism, Study
Design, Duration,
and Population SSRI Results
PM, EM
Retrospective, case- Fluoxetine, paroxetine, No associations with extrapyramidal symptoms
control, Swedish sertraline, citalopram, were noted
(n=19)13 fluvoxamine
Prospective, 12 wks, Paroxetine No associations with nausea were noted
Japanese (n=72)14
Prospective, ≥ 2 wks, Paroxetine No associations with nausea were noted
Japanese (n=78)23
Prospective, 6 wks, Fluoxetine No associations with ADRs were noted
New Zealander (n=65)33
LM, NM
Prospective, 12 wks, Fluvoxamine LMs associated with a higher risk of gastrointestinal
Japanese (n=96)21 adverse effects than NMs (hazard ratio 1.821,
p=0.043)
PM, IM, EM
Prospective, 6 wks, Fluvoxamine No associations with nausea were noted
Japanese (n=49)34
PM, IM, EM, UM
Prospective, 8 wks, Paroxetine No associations with discontinuation or severity
American (n=120)18 of ADRs were noted
SSRI = selective serotonin reuptake inhibitor; ADR = adverse drug reaction; PM = poor metabolizer; EM = extensive metabolizer; IM =
intermediate metabolizer; UM = ultrarapid metabolizer; LM = low metabolizer; NM = normal metabolizer.
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clinical relevance of the measurable change in
clearance was not appreciable.
Emerging Trends
Although conflicting results for associations
with efficacy have diluted most pharmacogenetic
studies of SSRIs, clear trends seem to have
emerged with certain polymorphisms and the
risk of adverse drug reactions. Multiple studies
have demonstrated reproducible associations
between SSRI-induced adverse drug reactions
and the G allele of the HTR2A -1438G/A variant
and the short (S) allele of SLC6A4 SERTPR. On
the other hand, no clear associations have been
established between CYP2D6 and the risk of
adverse drug reactions. However, novel polymor-
phisms associated with dopaminergic, seroton-
ergic, and glutaminergic neurotransmission must
be investigated more extensively to examine the
associations found and to continue generating
hypotheses regarding the role of these neuro-
transmitters in SSRI treatment. Newly published
data have shown an association between genetic
variation in the drug transport protein P-glyco-
protein and the antidepressant response.36
However, the relationship between P-glyco-
protein and adverse drug reactions is unknown.
Conclusion
The literature regarding the pharmacogenetics
of SSRI-associated adverse drug reactions is
emerging and currently dominated by retrospec-
tive studies of relatively few subjects with little
control over how the drugs were given. In addi-
tion, our understanding of the true mechanism of
action for SSRIs is evolving as we learn of
additional receptors and transporters that the
drugs target. Large, recent data sets such as that
collected in the STAR*D trial may offer
additional insights into mechanisms underlying
adverse drug reactions, as well as responses to
them. However, results of studies like these are
just starting to emerge.
In the future, pharmacogenetic association
studies will benefit from rational mechanisms
that relate functional changes to the pharmacology
of adverse drug reactions. As associations continue
to be elucidated and as studies are well replicated,
the next logical step will be to investigate the use
of prospective genotyping to guide SSRI phar-
macotherapy and evaluate therapeutic responses.
Maybe one day soon, pharmacogenetic studies
will help us realize the ultimate goal of delivering
personalized medical care.
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